Literature DB >> 15564746

Specific in vitro interaction between papillomavirus E2 proteins and TBP-associated factors.

Elba Carrillo1, Efrain Garrido, Patricio Gariglio.   

Abstract

The bovine and human papillomavirus (BPV/HPV) E2 proteins bind specifically to palindromic sequences ACCGN4CGGT that are concentrated within the viral long control region, where they regulate viral oncogene transcription. E2 can activate viral promoters over relatively large distances within the viral genome and was shown to cooperate with a number of cellular transcription factors. Transcriptional activator proteins, such as E2, are thought to act, at least in part, by influencing the assembly and/or stability of preinitiation complexes and it has been suggested that the transcription factor IID, composed by the TATA-binding protein (TBP) and numerous TBP-associated factors (TAFs), is a possible target of this important viral protein. In this paper, we demonstrate that E2 proteins associate in vitro with several TAFs, in particular with TAFII250 and TAFII80. In addition, we observed that the association of TAFII250 with BPV1 E2 is stronger than with HPV18 E2 and that the carboxy terminal domain of both viral proteins is involved in this interaction. On the other hand, TAFII80 binds with similar strength to both E2 proteins through their amino terminal region. These observations may help to explain the different behavior of bovine and human E2 proteins, since BPV E2 is a stronger transcriptional activator than HPV18 E2. 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564746     DOI: 10.1159/000080878

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  10 in total

1.  Acetylation of conserved lysines in bovine papillomavirus E2 by p300.

Authors:  Edward J Quinlan; Sara P Culleton; Shwu-Yuan Wu; Cheng-Ming Chiang; Elliot J Androphy
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

2.  HPV16 E2-mediated potentiation of NF-κB activation induced by TNF-α involves parallel activation of STAT3 with a reduction in E2-induced apoptosis.

Authors:  Devan Prabhavathy; Bandaru Niranjana Prabhakar; Devarajan Karunagaran
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

3.  HPV16 E2 could act as down-regulator in cellular genes implicated in apoptosis, proliferation and cell differentiation.

Authors:  Eric Ramírez-Salazar; Federico Centeno; Karen Nieto; Armando Valencia-Hernández; Mauricio Salcedo; Efraín Garrido
Journal:  Virol J       Date:  2011-05-20       Impact factor: 4.099

4.  Small molecule inhibitors of human papillomavirus protein - protein interactions.

Authors:  C M D'Abramo; J Archambault
Journal:  Open Virol J       Date:  2011-07-04

5.  Infection Strategies of Bacterial and Viral Pathogens through Pathogen-Human Protein-Protein Interactions.

Authors:  Saliha Durmuş Tekir; Tunahan Cakir; Kutlu Ö Ulgen
Journal:  Front Microbiol       Date:  2012-02-14       Impact factor: 5.640

6.  Comparative interactomics for virus-human protein-protein interactions: DNA viruses versus RNA viruses.

Authors:  Saliha Durmuş; Kutlu Ö Ülgen
Journal:  FEBS Open Bio       Date:  2017-01-04       Impact factor: 2.693

7.  Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF.

Authors:  Sarah Mole; Steven G Milligan; Sheila V Graham
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

8.  The HPV E2-Host Protein-Protein Interactions: A Complex Hijacking of the Cellular Network.

Authors:  Mandy Muller; Caroline Demeret
Journal:  Open Virol J       Date:  2012-12-28

9.  The landscape of human proteins interacting with viruses and other pathogens.

Authors:  Matthew D Dyer; T M Murali; Bruno W Sobral
Journal:  PLoS Pathog       Date:  2008-02-08       Impact factor: 6.823

Review 10.  Targeting TBP-Associated Factors in Ovarian Cancer.

Authors:  Jennifer R Ribeiro; Lindsay A Lovasco; Barbara C Vanderhyden; Richard N Freiman
Journal:  Front Oncol       Date:  2014-03-11       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.